Gregory L Conn

Title: Gregory L Conn: Innovator in Vascular Growth Factors

Introduction

Gregory L Conn is a notable inventor based in Bedford Hill, NY (US). He has made significant contributions to the field of biotechnology, particularly in the area of vascular growth factors. With a total of 5 patents to his name, Conn's work has implications for both medical research and therapeutic applications.

Latest Patents

Conn's latest patents focus on DNA molecules encoding vascular endothelial cell growth factor II subunits. This growth factor is purified from the culture media used to maintain mammalian glioma cells. The protein is a heterodimer that stimulates mitogenesis of mammalian vascular endothelial cells. It is particularly useful for promoting vascular development and repair. Additionally, this unique growth factor plays a crucial role in tissue repair, making it a valuable asset in regenerative medicine.

Career Highlights

Gregory L Conn is associated with Merck & Company, Inc., a leading global healthcare company. His work at Merck has allowed him to explore innovative solutions in the field of vascular biology. Conn's research has contributed to advancements in understanding how vascular endothelial cell growth factors can be utilized in therapeutic contexts.

Collaborations

Some of Conn's notable coworkers include Marvin L Bayne and Kenneth A Thomas, Jr. Their collaborative efforts have furthered research in vascular biology and have led to significant advancements in the field.

Conclusion

Gregory L Conn's contributions to the field of vascular growth factors highlight his role as an innovator in biotechnology. His patents and research continue to influence the development of therapies aimed at promoting vascular health and tissue repair.